Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
株価
$0.28545656
時価総額
$4.50M
変化(1日)
5.97%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)の発行済株式数
June 2024 時点の発行済株式数 15.76M
Acticor Biotech SAS の最新の財務報告および株価によると、現在の発行済株式数は 15.76M です。December 2022 の終わりには、同社は 10.55M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Acticor Biotech SAS(ALACT)の発行済株式数の履歴(2010 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 15.76M 30.55%
2023 12.07M 14.44%
2022 10.55M 35.54%
2021 7.78M 22.37%
2020 6.36M 21.38%
2019 5.24M 70.67%
2018 3.07M -7.38%
2017 3.31M 0.00%
2016 3.31M 0.00%
2015 3.31M 0.00%
2014 3.31M 0.00%
2013 3.31M 0.71%
2012 3.29M 0.00%
2011 3.29M -34.01%
2010 4.99M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
4.45B 28,130.95%
DK
253.90M 1,511.53%
US
102.90M 553.12%
US
190.00M 1,105.93%
BE
483.58M 2,969.30%
AU